Number of marketed drugs

Year No. of drugs on the market No. of drugs No. of drugs New chemical Chemical entitiesapproved withdrawn entities accumulated

1970 2.038 113 1461980 1.986 62 921988 2.108 118 91 181989 2.180 124 52 231990 2.209 109 80 191991 2.223 97 83 101992 2.244 113 92 221993 2.303 121 62 161994 2.355 128 78 301995 2.418 141 78 151996 2.492 172 93 311997 2.630 253 170 46 980

Source: The Norwegian Medicines Control Authority

Number of marketed drugs manufactured in Norway and abroad

1992

Manufac-tured

abroad79 %

Manufac-tured in Norway21 %

1997

Manufac-tured abroad85 %

Manufac-tured in Norway15 %

The top 20 pharmaceutical companies on the Norwegian market, 1998

Sales, veterinary products excluded

Total sales 1998, pharmacy purchase price mill NOK

1 MSD (Norge) A/S 6042 Glaxo Wellcome AS 5003 Astra Norge AS 4564 Pharmacia & Upjohn AS 4075 Nycomed AS 3486 Pfizer A/S 3137 Novo Nordisk Pharma AS 3058 Paranova A/S 2329 Novartis Norge A/S 198

10 Zeneca AS 18211 Weifa AS 17812 Alpharma AS 17413 Janssen-Cilag AS 14714 Bristol-Myers Squibb Norway ltd 13815 Eli Lilly Norge A.S 12716 Rhone-Poulenc Rorer AS 11817 H. Lundbeck A/S 10918 Roche Norge A/S 10719 Searle Scandinavia, div. of monsanto norway a/s 9920 Organon A/S 84

Company

The top 25 drugs in Norway, by value, 1998

The top 25 drugs represent 2,175 mill NOK, corresponding to approximately 35% of the total sales on pharmacy purchase levelSource: FARMASTAT

Product Main indication Total sales 1998, Defined daily doses pharmacy purchase price (DDD) per 1.000

mill NOK inhabitants per day.1 Zocor Høyt kolesterol / High cholesterol 287 23,52 Losec Magesår / Gastric Ulcer 179 7,93 Norvasc Høyt blodtrykk / High blood pressure 134 18,84 Pulmicort Astma / Asthma 120 12,25 Renitec Høyt blodtrykk / High blood pressure 107 19,36 Imigran Migrene / Migraine 101 0,87 Flutide Astma / Asthma 97 7,18 Seroxat Depresjon / Depression 97 8,29 Cipramil Depresjon / Depression 89 7,6

10 Serevent Astma / Asthma 80 6,511 Lipitor Høyt kolesterol/ High cholesterol 79 8,012 Insulin Insulatard Sukkersyke / Diabetes 76 6,613 Selo-Zok Høyt blodtrykk / High blood pressure 73 9,914 Sandimmun Neoral Nedsatt immunforsvar / Immune suppression 72 0,515 Carduran Høyt blodtrykk / High blood pressure 69 8,216 Ventoline Astma / Asthma 65 10,917 Paracet Smerter / Pain 61 14,218 Zyrtec Allergi / Allergy 61 15,019 Cozaar Høyt blodtrykk / High blood pressure 55 5,820 Zestril Høyt blodtrykk / High blood pressure 52 9,821 Zyprexa Schizofreni / Schizophrenia 50 0,822 Zoladex Kreft / Cancer 45 0,723 Zoloft Depresjon / Depression 44 3,724 Paralgin forte Smerter / Pain 42 9,425 Lanzo Magesår / Gastric ulcer 41 2,0

The top 10 drugs in Norway, by units, 1998.

ProductNumber of units

sold (x 1000

Several products on this list are painkillers. Albyl-E is in addition to being a painkiller also used as an anticoagulant in low doses.Otrivin, Rhinox and zymelin are nasal decongestants, in cold. Source: FARMASTAT

1 Paracet 6.2402 Ibux 1.7623 Otrivin 1.5524 Paralgin forte 1.0105 Rhinox 9156 Pinex 8667 Albyl-E 7938 Panodil 7689 Pamol 740

10 Zymelin 569

Sales of drugs distributed on therapeutic groups (ATC), 1996 and 1997

ATC groups Sales 1996 Change 1996-1997 Sales 1997 Share 1997

C Cardiovascular system 1.565 12,90 % 1.766N Central nervous system 1.560 6,10 % 1.654R Respiratory system 1.094 7,40 % 1.175A Alimentary and metabolism 926 11,80 % 1.035J Systemic antiinfectives 504 8,00 % 545B Blood and bloodforming organs 406 8,10 % 438G Urogenitals and sex hormones 351 9,20 % 383M Musculo-skeletal system 295 20,90 % 356L Antineoplastics and immunosuppressives 287 21,20 % 348D Dermatologicals 260 3,80 % 270S Sensory organs 224 3,90 % 233H Systemic hormones excl. sex hormones 212 3,90 % 220V Various 141 8,70 % 153Q Veterinary products 116 6,00 % 123P Antiparasitic products 22 1,50 % 22

Total 7.961 9,60 % 8.722

Number of units of drugs sold distributed on non-prescription and prescription drugs, 1998

Distribution, total number of units

Non-presription45 %

Prescription55 %

65.5 million units of drugs were sold in 1998. 55% of these were prescription drugs and 45% were non-prescription drugs. 47% of all prescriptions handled in the pharmacies are reimbursable prescriptions (blue-prescriptions). There are in average more units prescribed per blue prescription in comparison with white prescriptions (non-reimbursable) - 55% of all units of prescription drugs sold are reimbursable.

Kilde/Source: Norges Apotekerforening, FARMASTAT, The Norwegian Association of Proprietor Pharmacists, FARMASTAT

Prescription drugs - percentage reimbursable, 1997

Distribution, units of prescription drugs

Reimbursable55%

Non-reimbursable45 %

65.5 million units of drugs were sold in 1998. 55% of these were prescription drugs and 45% were non-prescription drugs. 47% of all prescriptions handled in the pharmacies are reimbursable prescriptions (blue-prescriptions). There are in average more units prescribed per blue prescription in comparison with white prescriptions (non-reimbursable) - 55% of all units of prescription drugs sold are reimbursable.

Source: The Norwegian Association of Proprietor Pharmacists, FARMASTAT

Prescription drugs - percentage reimbursable, 1997

Distribution, number of prescriptions

Non-reimbursable prescriptions (white)

53%

Reimbursable prescriptions

(blue)47 %

65.5 million units of drugs were sold in 1998. 55% of these were prescription drugs and 45% were non-prescription drugs. 47% of all prescriptions handled in the pharmacies are reimbursable prescriptions (blue-prescriptions). There are in average more units prescribed per blue prescription in comparison with white prescriptions (non-reimbursable) - 55% of all units of prescription drugs sold are reimbursable.

Source: The Norwegian Association of Proprietor Pharmacists, FARMASTAT

Private pharmacies’ composition of sales, 1997

Prescription drugs71,2 %

Non-pharmaceuticals13,5 %

Other goods3,4 %

Non-prescription drugs (OTC)11,9 %

Source: The Norwegian Association of Proprietor Pharmacists

Sales of drugs in Norway, fixed and variable prices, 1980 - 1998

Source: Norwegian Board of Health and Statistics Norway

Year Pharmacy drug sale Pharmacy drug sales Pharmacy drug sales Pharmacy drug pr. capita (1998 currency) sales pr. capita (1998 currency)

Mill. NOK NOK Mill. NOK NOK1980 1.515 370 3.773 9211985 2.701 649 4.368 1.0491990 4.967 1.169 5.934 1.3971991 5.484 1.283 6.335 1.4821992 5.838 1.358 6.590 1.5331993 6.418 1.484 7.082 1.6381994 6.729 1.547 7.323 1.6841995 7.577 1.734 8.049 1.8421996 8.169 1.860 8.569 1.9511997 8.865 2.007 9.065 2.0521998 9.590 2.155 9.590 2.155

Distribution of the total drug sales. (Pharmacy retail level)

Veterinary products1,5 %

OTC12,0 %

National Insurance 54,0 %

Non-reimbursable prescription drugs

11,5 %

Patient co-payment6,0 %

Hospitals15,0 %

31.1% of the total drug bill is covered by the consumers. The patients’ contribution is distributed on non-reimbursable drugs, non-prescription drugs, veterinary products and co-payment for reimbursable drugs. The diagram is made by using data from various sources and should only be used with that in mind

Source: LMI

Public health care and drug expenditure, 1988 - 1997

1)National Insurance and hospitals2) % of public health care expenditure

Source: Statistics Norway and The Norwegian Board of Health

Public drug expenditure 1) per capita

1988 639.591 42.351 6,6 2.573 6,1 6101989 682.347 43.105 6,3 2.806 6,5 6631990 722.071 45.675 6,3 3.191 7 7511991 762.774 50.352 6,6 3.582 7,1 8381992 784.296 52.550 6,7 3.953 7,5 9191993 823.339 54.036 6,6 4.277 7,9 9891994 869.742 56.145 6,5 4.585 8,2 1.0541995 925.866 60.390 6,5 5.053 8,5 1.1561996 1.017.794 65.850 6,5 5.454 8,3 1.2421997 1.084.788 71.985 6,6 6.109 8,5 1.383

Public health care expenditureGDP

NOKmill NOK % 2)% of GDPmill NOKmill NOKYear

Public drug expenditure 1)

National Insurance Administration drug expenditure, percent increase, 1989 - 1998

14,9

11,8

7,8

12,5

11,2

12,5

8,910,7

15,2

0

4

8

12

16

1989-90 1990-91 1991-92 1992-93 1993-94 1994-95 1995-96 1996-97 1997-98

% C

han

ge

Source:National Insurance Administration

Drug expenditure in private and public sector, 1989 - 1997

Sales on pharmacy retail level

Source: The Norwegian Board of Health

År TotalYear

mill NOK mill NOK % mill NOK % mill NOK %

1989 4.350 821 18,9 1.985 45,6 1.544 35,51990 4.967 904 18,2 2.287 46 1.776 35,81991 5.484 955 17,4 2.627 47,9 1.902 34,71992 5.838 1.016 17,4 2.937 50,3 1.885 32,31993 6.418 1.079 16,8 3.198 49,8 2.141 33,41994 6.729 1.135 16,9 3.450 51,3 2.144 31,91995 7.577 1.169 15,4 3.884 51,3 2.524 33,31996 8.169 1.156 14,2 4.298 52,6 2.715 33,21997 8.865 1.330 15 4.779 53,9 2.756 31,1

Hospital National insurance Private share

Drug expenditure in private and public sector, 1989 - 1997

Sales on pharmacy retail level

45,6 4647,9

50,3 49,851,3 51,3 52,6 53,9

18,9 18,21514,215,416,916,817,417,4

34,731,1

33,233,331,9

33,432,335,5 35,8

0

10

20

30

40

50

60

1989 1990 1991 1992 1993 1994 1995 1996 1997

Hospitals

National insurance,reimbursement of drugs

Private share

Source: The Norwegian Board of Health

Public drug expenditure* (1997-currency)

31073372

3636 37834000

42684549

4967

0

1000

2000

3000

4000

5000

6000

1990 1991 1992 1993 1994 1995 1996 1997

Public drug expenditure excl.VAT

VAT

* National insurance and hospitalsThe figures are in 1997-currency (corrected by the consumer price index)VAT in Norway was 20% until 31.12.1992. It was increased to 22% on 01.01.1993 and to 23% on 01.01.1995.Source: The Norwegian Board of Health

Public drug expenditure, percent increase, excl. VAT, (1997-currency)

8,57,8

4

5,7

6,7 6,6

9,2

0

1

2

3

4

5

6

7

8

9

10

1990-91 1991-92 1992-93 1993-94 1994-95 1995-96 1996-97

Per

cen

t

Public drug expenditure: National Insurance and hospital. The increase in expenditure is calculated in 1997-currency(corrected by the consumer price index)

Source: The Norwegian Board of Health

The share of innovative drugs of the total sales, 1993 - 1998

Sales in mill NOK, 1998-currency, on pharmacy purchase level

0

1000

2000

3000

4000

5000

6000

7000

1993 1994 1995 1996 1997 1998

Innovative drugsNon-innovative drugs

Source: LMI

Public health care expenditures, NOK per capita, 1997

17482

11386

4707

1389

0

5000

10000

15000

20000

Total Institutions Others Pharmaceuticales,devices, equipment etc.

Source: Statistics Norway

Consumer expenditure on pharmaceuticals compared to other expenses NOK per capita, 1997

624

1940

3701

4868

5145

13166

0 2000 4000 6000 8000 10000 12000 14000

Pharmaceuticals

Postage and telephone

Refreshments andtobacco

Electricity and heating

Clothing

Food

Source: Statistics Norway and Norwegian Board of Health

Norway’s import and export of pharmaceutical products, 1988 - 1997

0

500

1000

1500

2000

2500

3000

3500

4000

4500

1988 1989 1990 1991 1992 1993 1994 1995 1996 1997

Mil

l N

OK

ImportEksport

Source: Statistics Norway, based on OECD Standard International Trade Classification (SITC) division 54

Import distributed on countries of origin, 1997

USA3,8 % Others

11,0 %

Sweden20,0 %

Netherlands17,2 %

Germany11,4 %

Denmark10,6 %

UK8,6 %

Switzerland7,1 %

Belgium5,7 %

France4,6 %

Total import 1997: 4.363 mill NOKSource:Statistics Norway, based on OECD Standard International Trade Classification (SITC) division 54

Export distributed on export countries, 1997

USA8,2 %

Finland5,2 %

Japan4,0 %

UK4,0 %

Italy3,8 %

Others31,5 %

Sweden17,2 %

Austria9,0 %

Denmark8,5 %

Ireland8,6 %

Total export 1997: 1.537 mill NOKSource:Statistics Norway, based on OECD Standard International Trade Classification (SITC) division 54

The Pharmaceutical Industry’s investments in research and development (R & D) in Norway,

NOK million, 1995 - 1997

592,5

571,4

602

555560565570575580

585590595600605

1995 1996 1997

Mil

l N

OK

Source: LMI

The Pharmaceutical Industry’s investments in research and development (R & D) in percent of drug sales in Norway

(pharmacy purchase price), 1995 - 1997

Source: LMI

12,5

11,210,8

5

6

7

8

9

10

11

12

13

1995 1996 1997

%

Parallel imported drug sales in Norway, 1995 - 1998 (pharmacy purchase price in NOK million)

Source: FARMASTAT

9,1

69,8

191,6

421,3

0

100

200

300

400

500

1995 1996 1997 1998

Mil

l N

OK

Percentage of drug sales 0,2 1,4 3,4 6,9

Structural effects in sales, (pharmacy purchase price), 1989-1998

8,9

13,4

9,9

7,5

12,1

10,3

2 2,3

5,2

2,7

-1,2

-2,4

-0,9-1

3,7 3,8

5

0,8

4,1

7,9

6,7 6,65,5

6,1 6,45,3 5,3

9,5

8,2

10,6

12,7

0,7 0,1

-0,1

1,6

5,9

2,4

5,3

7,55,8

-3

0

3

6

9

12

15

1989 1990 1991 1992 1993 1994 1995 1996 1997 1998

Total increase in sales

Change in prices

Change in volume

Change due to new drugs

Total sales increased by 10.3% in 1998 (pharmacy purchase price). The increase is caused by a price reduction of -0.9%, an increase in number of doses (change in quantity) of 5.9% and change due to new drugs of 5.3%.

Source: Norwegian Medicinal Depot

Prices on drugs - divided on the distributors, 1996

VAT18,7 %

Manufacturer58,7 %

Wholesaler4,5 %

Pharmacy18,1 %

Prescription and non-prescription drugs.

Source: Norwegian Competition Authority

Price changes on drugs (pharmacy purchase price) and general inflation, annual percent increase,

1993-1998

1,4

2,4

1,3

2,62,3

1,5 1,6 1,6

3,5

4,6

-2,4

0,7

-0,1

0,1

-0,9

-3

-2

-1

0

1

2

3

4

5

1993-94 1994-95 1995-96 1996-97 1997-98

Consumer price index

Food

Drugs

Source: Statistics Norway, Norwegian Medicinal Depot

Leading Corporate Groups, Global Performance, 1996

Company billion USD Market share, %

Total market 296,4 1001 Novartis 9,8 4,42 Glaxo Wellcome 9,8 4,43 Merck & Co 8,9 4,04 Hoechst Marion Roussel 7,4 3,35 Bristol Myers Squibb 7,1 3,26 Johnson & Johnson 6,9 3,17 American Home Products 6,9 3,18 Pfizer 6,9 3,19 SmithKline Beecham 6,0 2,7

10 Roche 6,0 2,7Top 10 75,7 34,0

Source: IMS International, Pharmaceutical World Review (Presented by MEFA in Facts, 1997)

Leading products world-wide, 1996

Source: Scrip Magazine, 1998 (Presented by LIF in Facts, 1998)

Product, Company Main indication mill USD1 Losec, Astra Magesår / Gastric Ulcer 4.3312 Zantac, Glaxo Wellcome Magesår / Gastric Ulcer 3.0163 Renitec, MSD Høyt blodtrykk / High blood pressure 2.8194 Zocor, MSD Høyt kolesterol / High cholesterol 2.8005 Epogen, Amgen Anemi / Anaemia 2.5176 Pravachol, Bristol myers-squibb Høyt kolesterol / High cholesterol 2.4937 Adalat, Bayer Høyt blodtrykk / High blood pressure 2.3938 Fontex, Eli Lilly Depresjon / Depression 2.356 9 Humulin, Eli Lilly Sukkersyke / Diabetes 2.176

10 Norvasc, Pfizer Høyt blodtrykk / High blood pressure 1.795

Price level on drugs in some European countries, 1998

Norway = 100

88,6

91,5

93,5

94

97,3

100

102,1

103,5

104,9

108,1

119,6

122,3

0 10 20 30 40 50 60 70 80 90 100 110 120 130

France

Finland

Austria

Italy

Sweden

Norway

Denmark

Belgium

The Netherlands

Germany

UK

Switzerland

The price index is calculated from pharmacy purchase prices and Swedish volumes in 1997, and exchange rates per 2.1.98. The pharmacy purchase prices are from each country’s pharmacy price lists.Source.: Apoteket AB, Sweden. (The figures are calculated to Norway = 100)

Pharmaceutical consumption per capita in Europe, 1997

98

99

109

122

134

135

154

155

157

166

179

192

205

216

216

237

0 20 40 60 80 100 120 140 160 180 200 220 240

Grecce

Ireland

UK

The Netherlands

Spain

Norway

Denmark

Italy

Portugal

Austria

Finland

Germany

Sweden

Belgium

Switzerland

France

The figures are calculated on the basis of sources, using methods specific to each country. Strict comparisons between countries may therefore not be reliable.

Source: EFPIA

Health expenditure in OECD-countries, 1996Totale helseutgifter i % av BNP / Total health expenditure in % of GDP

10,59,7 9,7 9,6

8,6 8,5 8,3 8,2 8 7,9 7,8 7,7 7,4 7,4 7,3 7,3 7,2 7,2 7 7 6,9 6,86,3

5 4,6 4,2 4

14

0

2

4

6

8

10

12

14

1994 -figures: TurkeyGDP: Gross Domestic ProductThe figure for Norway in the above diagram is different from the ones presented on page 15 due to different data sources.Source: OECD in figures, 1998

Public drug expenditure in percent of public healthcare expenses in some European countries, 1997

8,3

8,5

10,8

12

12,4

13,4

15

0 2 4 6 8 10 12 14 16

Denmark

Norway

Italy

Germany

Sweden

The Netherlands

Switzerland

%

Source: EFPIA

Composition of consumer prices (%) of medicine in Europe (pharmacy retail price), 1996

87,5

76,7

68,6

65,4

64,4

59,3

59,4

62,3

56,4

57

56,6

56,7

56,3

49,9

48

62,6

7,5

3,2

7,6

7

6,7

8,1

4,5

12

8,5

10

8,5

4

8,8

5,8

4

10,3

5

20,1

19

25,5

25

28,8

17,4

20

33,1

33

29,2

19,3

21,9

24

29

27,1

4,8

2,1

3,9

3,8

18,7

5,7

2

5,7

20

13

20,3

19

0 % 10 % 20 % 30 % 40 % 50 % 60 % 70 % 80 % 90 % 100 %

Ex factory price

Wholesaler's margin

Pharmacy,s margin

VAT

Source: EFPIA (presented by LIF in Facts, 1998)

1. The ”official” wholesaler’s margin is 12,5%, but of this 7,5 % is passed on to the Pharmacists as incentive bonus.

VAT; Zero on prescrption medicines and 17,5 % on OTC.

2. VAT on OTC are 25 % and no VAT on prescription drugs.

3. VAT on OTC are 5 %

4. Prescription only medicine.

5. Prices are on oral medicine only

6. 1997- figures

7. Reimburable medicine.

8. Local manufactures only. Other taxes (13,0 %), besides VAT (7,4 %)

9. VAT and Pharmacy fee.

Composition of consumer prices (%) of medicine in Europe (pharmacy retail price), 1996 Page 2

VAT on drugs and other products and services in Europe, 1999

Country Standard VAT rate Prescription Non-prescriptionDenmark 25 25 25Norway 23 23 23Germany 16 16 16Italy 20 10 10Finland 22 8 8Greece 18 8 8Belgium 21 6 6Netherlands 17,5 6 6Portugal 17 5 5Spain 16 4 4France 1) 20,6 2,1 - 5,5 2,1 - 5,5Switzerland 7,5 2,3 2,3Ireland 2) 21 0 - 21,0 0 - 21,0Austria 3) 20 0 - 20,0 0 - 20,0Sweden 25 0 25UK 17,5 0 17,5

VAT rates on drugs

VAT RATES APPLIED TO MEDICINES PER FEBRUARY 1, 19991)FRANCE: Reimbursable medicines 2.1%. Non-reimbursable medicines 5.5%2) IRELAND: Oral medication 0%, other medication 21%3)AUSTRIA: 0% for medicines covered by health insuranceSource: EFPIA

The most common causes of death, 1995

23

17

11

5

44

Cau

ses

of d

etah

in

%

Cardiovascular diseases

Tumors

Other diseases

Respiratory diseases

Violent deaths

Source: Statistics Norway

Disablement pensions according to diagnosis, 1997

Accidents, poisioning and

violence 5 %

Nervous system and sensory organ

diseases 7 %

Mental diseases29 %

Circulatory diseases

8 %

Musculoskeletal system diseases

33 %

Other causes18 %

Total number of disablement pensions per December 1997: 246 541

Source: National Insurance Administration

Expenditures of the National Insurance (NOK billion), 1998

0,9

3,3

4,2

5,3

5,3

13,8

14,4

16,5

28,1

58,5

0 10 20 30 40 50 60 70

Other costs

Administration

Occupational rehabilitation

Drugs

Unemploment benefits

Healthcare

Social benefits

Sickness benefits

Disablement

Retirement

NOK billion

Source: National Insurance Administration

Expenditures of the National Insurance

National Insurance Administration’s expenditures in 1998: NOK 150 355 millions

Source: National Insurance Administration

Drug expenditures of the National Insurance

3,5 %

Other costs of the National Insurance

96,5 %

Operating costs at the largest hospital in Norway, (Ullevål hospital) in 1996 and 1997 (percent share)

63,3

28,4

3,3

69,4

27,4

3,2

0

25

50

75

Salaries and socialcosts

Other costs Drugs

Per

cen

t

19961997

Source: Ullevål Hospital

Prescription statistics, 1997. Reimbursable drugs, distribution of sales on

reimbursement groups

CNS disorders11 %

Cardiovascular diseases

33 %

Diabetes5 %

Asthma14 %

Others26 %

Oesophageal Reflux disease

5 %

Allergy6 %

Calculated on the basis of sales from a selection of pharmacies

Source:The Norwegian Association of Proprietor Pharmacists

Key figures for hospital admissions

Hospital beds

22 687

17 19015 617 15 140 15 314 15 181 15 028

1980 1990 1993 1994 1995 1996 1997

Nu

mb

er

Key figures for hospital admissions

Average hospitalization days

10,69,8

8,07,4

6,8 6,6 6,5 6,4

1980 1984 1988 1990 1994 1995 1996 1997

Day

s

Source: Statistics Norway

Key figures for hospital admissions

Discharges

604 269612 724

605 552610 611 610 611

627 032633 982

651 710662 881

1989 1990 1991 1992 1993 1994 1995 1996 1997

Nu

mb

er o

f p

atie

nts

Inhabitants per physician and per dentist, 1994 - 1998

850 836 823 801 782

232242272298 284

0

100

200

300

400

500

600

700

800

900

1994 1995 1996 1997 1998

Nu

mb

er

Inhabitants perphysician

Inhabitants perdentist

Source: The Norwegian Board of Helth and Statistics Norway

Inhabitants per pharmacy, 1994 - 1998

12495 12310 12068 11843 11569

0

5000

10000

15000

1994 1995 1996 1997 1998

Nu

mb

er

Source: The Norwegian Board of Health and Statistics Norway